172 related articles for article (PubMed ID: 12761499)
1. Allelic phasing of a mouse chromosome 11 deficiency influences p53 tumorigenicity.
Biggs PJ; Vogel H; Sage M; Martin LA; Donehower LA; Bradley A
Oncogene; 2003 May; 22(21):3288-96. PubMed ID: 12761499
[TBL] [Abstract][Full Text] [Related]
2. Identification and characterization of potential human carcinogens using B6.129tm1Trp53 heterozygous null mice and loss of heterozygosity at the Trp53 locus.
French JE
IARC Sci Publ; 2004; (157):271-87. PubMed ID: 15055301
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer.
Birgisdottir V; Stefansson OA; Bodvarsdottir SK; Hilmarsdottir H; Jonasson JG; Eyfjord JE
Breast Cancer Res; 2006; 8(4):R38. PubMed ID: 16846527
[TBL] [Abstract][Full Text] [Related]
4. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours.
Donehower LA; Harvey M; Slagle BL; McArthur MJ; Montgomery CA; Butel JS; Bradley A
Nature; 1992 Mar; 356(6366):215-21. PubMed ID: 1552940
[TBL] [Abstract][Full Text] [Related]
5. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
[TBL] [Abstract][Full Text] [Related]
6. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer.
Jonkers J; Meuwissen R; van der Gulden H; Peterse H; van der Valk M; Berns A
Nat Genet; 2001 Dec; 29(4):418-25. PubMed ID: 11694875
[TBL] [Abstract][Full Text] [Related]
7. CGH analysis of familial non-BRCA1/BRCA2 breast tumors and mutation screening of a candidate locus on chromosome 17q11.2-12.
Maguire P; Holmberg K; Kost-Alimova M; Imreh S; Skoog L; Lindblom A
Int J Mol Med; 2005 Jul; 16(1):135-41. PubMed ID: 15942690
[TBL] [Abstract][Full Text] [Related]
8. Loss of p53 in benzene-induced thymic lymphomas in p53+/- mice: evidence of chromosomal recombination.
Boley SE; Anderson EE; French JE; Donehower LA; Walker DB; Recio L
Cancer Res; 2000 Jun; 60(11):2831-5. PubMed ID: 10850423
[TBL] [Abstract][Full Text] [Related]
9. Expression analysis of candidate breast tumour suppressor genes on chromosome 16q.
van Wezel T; Lombaerts M; van Roon EH; Philippo K; Baelde HJ; Szuhai K; Cornelisse CJ; Cleton-Jansen AM
Breast Cancer Res; 2005; 7(6):R998-1004. PubMed ID: 16280054
[TBL] [Abstract][Full Text] [Related]
10. Refining the relation between 'first hits' and 'second hits' at the APC locus: the 'loose fit' model and evidence for differences in somatic mutation spectra among patients.
Crabtree M; Sieber OM; Lipton L; Hodgson SV; Lamlum H; Thomas HJ; Neale K; Phillips RK; Heinimann K; Tomlinson IP
Oncogene; 2003 Jul; 22(27):4257-65. PubMed ID: 12833148
[TBL] [Abstract][Full Text] [Related]
11. Mice with alterations in both p53 and Ink4a/Arf display a striking increase in lung tumor multiplicity and progression: differential chemopreventive effect of budesonide in wild-type and mutant A/J mice.
Wang Y; Zhang Z; Kastens E; Lubet RA; You M
Cancer Res; 2003 Aug; 63(15):4389-95. PubMed ID: 12907609
[TBL] [Abstract][Full Text] [Related]
12. Novel somatic mutations in the BRCA1 gene in sporadic breast tumors.
Janatova M; Zikan M; Dundr P; Matous B; Pohlreich P
Hum Mutat; 2005 Mar; 25(3):319. PubMed ID: 15712267
[TBL] [Abstract][Full Text] [Related]
13. Cooperative tumorigenic effects of germline mutations in Rb and p53.
Williams BO; Remington L; Albert DM; Mukai S; Bronson RT; Jacks T
Nat Genet; 1994 Aug; 7(4):480-4. PubMed ID: 7951317
[TBL] [Abstract][Full Text] [Related]
14. Meningiomas: analysis of loss of heterozygosity on chromosome 10 in tumor progression and the delineation of four regions of chromosomal deletion in common with other cancers.
Mihaila D; Gutiérrez JA; Rosenblum ML; Newsham IF; Bögler O; Rempel SA;
Clin Cancer Res; 2003 Oct; 9(12):4435-42. PubMed ID: 14555516
[TBL] [Abstract][Full Text] [Related]
15. Insights into aging obtained from p53 mutant mouse models.
Dumble M; Gatza C; Tyner S; Venkatachalam S; Donehower LA
Ann N Y Acad Sci; 2004 Jun; 1019():171-7. PubMed ID: 15247009
[TBL] [Abstract][Full Text] [Related]
16. Characterization of familial non-BRCA1/2 breast tumors by loss of heterozygosity and immunophenotyping.
Oldenburg RA; Kroeze-Jansema K; Meijers-Heijboer H; van Asperen CJ; Hoogerbrugge N; van Leeuwen I; Vasen HF; Cleton-Jansen AM; Kraan J; Houwing-Duistermaat JJ; Morreau H; Cornelisse CJ; Devilee P
Clin Cancer Res; 2006 Mar; 12(6):1693-700. PubMed ID: 16551851
[TBL] [Abstract][Full Text] [Related]
17. Fine allelotyping of Erbb2-induced mammary tumors in mice reveals multiple discontinuous candidate regions of tumor-suppressor loci.
Cool M; Depault F; Jolicoeur P
Genes Chromosomes Cancer; 2006 Feb; 45(2):191-202. PubMed ID: 16258954
[TBL] [Abstract][Full Text] [Related]
18. High-resolution 19p13.2-13.3 allelotyping of breast carcinomas demonstrates frequent loss of heterozygosity.
Yang TL; Su YR; Huang CS; Yu JC; Lo YL; Wu PE; Shen CY
Genes Chromosomes Cancer; 2004 Nov; 41(3):250-6. PubMed ID: 15334548
[TBL] [Abstract][Full Text] [Related]
19. Somatic TP53 mutations are relatively rare among adrenocortical cancers with the frequent 17p13 loss of heterozygosity.
Libè R; Groussin L; Tissier F; Elie C; René-Corail F; Fratticci A; Jullian E; Beck-Peccoz P; Bertagna X; Gicquel C; Bertherat J
Clin Cancer Res; 2007 Feb; 13(3):844-50. PubMed ID: 17289876
[TBL] [Abstract][Full Text] [Related]
20. Long-term infection with Helicobacter felis and inactivation of the tumour suppressor gene p53 cumulatively enhance the gastric mutation frequency in Big Blue transgenic mice.
Jenks PJ; Jeremy AH; Robinson PA; Walker MM; Crabtree JE
J Pathol; 2003 Dec; 201(4):596-602. PubMed ID: 14648663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
